MOTS-C: Uses, Dosage Ranges, Safety & Legal Status (2026)

Editorially reviewed · Last updated June 2026 · This article is educational and is not medical advice. Talk to a licensed clinician before using any peptide.

What is MOTS-C?

MOTS-C ("Mitochondrial Open reading frame of the Twelve S rRNA type-C") is a mitochondrial-derived peptide — a 16–amino-acid sequence encoded inside the mitochondrial 12S rRNA region rather than the cell nucleus. Your body makes it naturally, and levels are linked to metabolism and tend to decline with age.

Its studied mechanisms center on AMPK activation — a master metabolic switch — which is associated with better glucose handling, improved insulin sensitivity, and a shift toward "metabolic flexibility" (using fuel more efficiently). In animal models this has been linked to improved insulin resistance, exercise capacity, and metabolic and bone outcomes.

The honest summary, and it's more pointed than for most peptides: the mitochondrial-biology research is genuinely interesting, but MOTS-C as an injectable drug has essentially no large, completed, published human trials. Most of what's "known" about administering it comes from rodent studies and from observing the body's own MOTS-C levels — not from giving people the injectable product sold online.

What people use MOTS-C for

People most commonly report using MOTS-C for:

• Fat loss and general metabolic health
• Insulin sensitivity / blood-sugar support
• Energy and "mitochondrial function"
• Exercise performance and recovery
• Longevity / anti-aging stacks

Separate reported use from proven use here especially carefully. These applications rest on animal data and anecdote. The FDA itself reviewed MOTS-C for obesity and osteoporosis uses — reviewed is not the same as approved, and none of these uses is clinically established in humans.

Unlike recovery peptides such as BPC-157 or TB-500, MOTS-C sits in a metabolic lane closer to investigational weight-management compounds like retatrutide — though with far less human data and no medicine pathway.

MOTS-C dosage: commonly reported ranges

The figures below are commonly reported in community use and extrapolated from animal research. They are not a recommendation, a protocol, or a verified safe dose — and for MOTS-C the underlying human evidence is thinner than for almost any peptide on this site, so treat the numbers as especially speculative.

Community protocols for MOTS-C vary more than for better-known peptides precisely because there's so little to anchor them — no human dose-response data exists. Two plain-language cautions:

1. More is not "more metabolic benefit." There's no evidence base linking any of these amounts to safe or effective outcomes in people.
2. The dose is only as accurate as the source. Underdosed, overdosed, and contaminated "research chemical" vials are common — see sourcing below.

How MOTS-C is reconstituted

Injectable MOTS-C ships as a freeze-dried powder mixed with bacteriostatic water before use. The number of "units" you draw on an insulin syringe depends entirely on how much water you add to the vial, which is where most dosing errors happen. Use our peptide calculator to check draw volumes against your syringe size and to catch unit mistakes (mg versus mcg).

People who use it typically refrigerate the reconstituted vial, keep it out of light, and use sterile technique. If you can't reconstitute and measure accurately and sterilely, that alone is a reason not to inject. See the full peptide dosing protocols hub for other compounds.

MOTS-C side effects and safety

With no large human safety studies, the honest answer to "is it safe?" is we don't know — and MOTS-C has one regulator-flagged concern worth singling out:

• Possible immunogenicity (the standout MOTS-C flag).The FDA has said MOTS-C may pose a significant risk for immunogenicity for some routes of administration. "Immunogenicity" means the body may mount an unwanted immune response to the injected peptide — a real concern that's specific to how this one is delivered.
• Anecdotally reported, usually mild: injection-site irritation, fatigue, lightheadedness, nausea, headache.
• Unknown long-term effects.Because almost no one has been studied taking it, there's no good data on what repeated use does.
• Contamination and dosing risk from unregulated sourcing — arguably the most realistic near-term danger.

Stop and seek medical care for signs of injection-site infection (spreading redness, heat, pus, fever), any allergic-type reaction (hives, swelling, trouble breathing), or other unexpected symptoms.

Is MOTS-C legal in 2026?

MOTS-C sits in the same gray zone as other research peptides, and its status is actively in motion:

• It is not approved by the FDA for any human use.
• It is sold only as a "Research Use Only" / "research chemical, not for human consumption" product — a liability shield for the seller, not a safety clearance.
• This is under active FDA review: the FDA's Pharmacy Compounding Advisory Committee is scheduled to review MOTS-C (free base and acetate forms) on July 23–24, 2026, as a bulk drug substance being considered for the 503A Bulks List. Given the agency's stated immunogenicity concern, the outcome is genuinely uncertain.
• Athletes should assume it's prohibited. WADA's S0 category (non-approved substances) covers any pharmacological substance not approved by a regulatory health authority for human use — which describes MOTS-C. Tested athletes and service members should treat it as off-limits.

For most individuals, possession isn't separately criminalized, but selling it for human use draws FDA enforcement, and using it makes you personally responsible for an unapproved, barely-studied product.

How to evaluate MOTS-C sourcing and quality

If someone is going to use it despite the above, sourcing is where the most avoidable harm lives:

• A recent, batch-specific Certificate of Analysis (COA) with HPLC purity (ideally ≥98%) and mass-spec identity confirmation.
• Independent third-party testing, not just the vendor's in-house lab.
• Sterile, properly sealed vials and clear storage guidance.
• Realistic claims — any vendor calling it "FDA-approved," a proven fat-loss drug, or a longevity cure is lying.

No COA, vague sourcing, or suspiciously low pricing are all reasons to walk away.

Who should not use MOTS-C

• Anyone pregnant or breastfeeding
• Anyone with an autoimmune or immune-related condition (given the immunogenicity flag)
• Anyone with diabetes or on blood-sugar–lowering medication, without clinical oversight (potential additive effects)
• Competitive or tested athletes and service members
• Anyone who can't get clinical oversight or verify their source
• Minors

References

• FDA — Pharmacy Compounding Advisory Committee meeting, July 23–24, 2026 (503A Bulks List review)
• FDA / industry reporting — MOTS-C immunogenicity concern and obesity/osteoporosis uses reviewed for compounding (2023)
• World Anti-Doping Agency — Prohibited List (S0, non-approved substances)
• Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab (2015)
• Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline. Cell Metab (2016)
• Kim KH, et al. MOTS-c modulates skeletal muscle and adipose tissue metabolism in mice. Diabetes (2017)